Search Results - "Wunderlich, Glen"

Impulse control disorders in parkinson disease: A multicenter case-control study by Voon, Valerie, Sohr, Mandy, Lang, Anthony E., Potenza, Marc N., Siderowf, Andrew D., Whetteckey, Jacqueline, Weintraub, Daniel, Wunderlich, Glen R., Stacy, Mark

“…Objective: To assess factors associated with impulse control disorders (ICDs) in Parkinson disease (PD) using a multicenter case–control design. Methods:…”
Get full text

Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer's dementia: a randomized controlled trial by Wunderlich, Glen, Blahova, Zuzana, Garcia, Miguel, Jessen, Frank

“…This phase II proof-of-concept study assessed the efficacy and safety of BI 425809, a novel selective glycine transporter-1 inhibitor, for the treatment of…”
Get full text

Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study by Weintraub, Daniel, Sohr, Mandy, Potenza, Marc N., Siderowf, Andrew D., Stacy, Mark, Voon, Valerie, Whetteckey, Jacqueline, Wunderlich, Glen R., Lang, Anthony E.

“…A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD). Analyzing…”
Get full text

Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease by Frölich, Lutz, Wunderlich, Glen, Thamer, Claus, Roehrle, Michael, Garcia, Jr, Miguel, Dubois, Bruno

“…There are currently no approved treatments for the prodromal stage of Alzheimer's disease (AD). Approved symptomatic treatments for mild-to-moderate AD include…”
Get full text

Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients by Weintraub, Daniel, Koester, Juergen, Potenza, Marc N, Siderowf, Andrew D, Stacy, Mark, Voon, Valerie, Whetteckey, Jacqueline, Wunderlich, Glen R, Lang, Anthony E

“…An association between dopamine-replacement therapies and impulse control disorders (ICDs) in Parkinson disease (PD) has been suggested in preliminary studies…”
Get more information

Building clinically relevant outcomes across the Alzheimer's disease spectrum by Rentz, Dorene M., Wessels, Alette M., Annapragada, Ananth V., Berger, Anna‐Karin, Edgar, Chris J., Gold, Michael, Miller, David S., Randolph, Christopher, Ryan, J. Michael, Wunderlich, Glen, Zoschg, Megan Canniere, Trépel, Dominic, Knopman, David S., Staffaroni, Adam M., Bain, Lisa J., Carrillo, Maria C., Weber, Christopher J.

“…Demonstrating that treatments are clinically meaningful across the Alzheimer's disease (AD) continuum is critical for meeting our goals of accelerating a cure…”
Get full text

Reliability and Validity of the Sexual Interest and Desire Inventory-Female (SIDI-F), a Scale Designed to Measure Severity of Female Hypoactive Sexual Desire Disorder by Clayton, Anita H., Segraves, R. Taylor, Leiblum, Sandra, Basson, Rosemary, Pyke, Robert, Cotton, Dan, Lewis-D'Agostino, Diane, Evans, Kenneth R., Sills, Terrence L., Wunderlich, Glen R.

“…The Sexual Interest and Desire Inventory-Female (SIDI-F) is a 13-item scale developed as a clinician-administered assessment tool to quantify the severity of…”
Get full text

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia by Rosenbrock, Holger, Desch, Michael, Wunderlich, Glen

“…Schizophrenia is a psychiatric disorder characterised by symptoms in three domains: positive (e.g. delusions, hallucinations), negative (e.g. social…”
Get full text

Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders? by Evans, Kenneth R, Sills, Terrence, Wunderlich, Glen R, McDonald, Heather P

“…A common practice in depression trials is to exclude patients whose depressive symptoms improve between Screen and Baseline evaluations under the assumption…”
Get full text

Validation of the Female Sexual Distress Scale-Revised for Assessing Distress in Women with Hypoactive Sexual Desire Disorder by DeRogatis, Leonard, Clayton, Anita, Lewis-D'Agostino, Diane, Wunderlich, Glen, Fu, Yali

“…The concept of sexually related personal distress is currently central to the diagnosis of all female sexual dysfunctions (FSD). In the current study, we have…”
Get full text

Decreased CCKB receptor binding in rat amygdala in animals demonstrating greater anxiety-like behavior by WUNDERLICH, Glen R, RAYMOND, Roger, DESOUSA, Norberto J, NOBREGA, José N, VACCARINO, Franco J

“…Abstract Rationale. The potentiation of the acoustic startle response (ASR) by stimuli associated with aversive events is mediated via the amygdala and is used…”
Get full text

Disruption of Spatial but Not Object-Recognition Memory by Neurotoxic Lesions of the Dorsal Hippocampus in Rats by Duva, Christopher A, Floresco, Stan B, Wunderlich, Glen R, Lao, Terrance L, Pinel, John P. J, Phillips, Anthony G

“…Ischemia-induced cell loss in the CA1 region of the dorsal hippocampus results in severe deficits on delayed non-matching-to-sample (DNMS), whereas…”
Get full text

Cholecystokinin modulation of locomotor behavior in rats is sensitized by chronic amphetamine and chronic restraint stress exposure by Wunderlich, Glen R, Rotzinger, Susan, Bush, David E.A, DeSousa, Norberto J, Vaccarino, Franco J

“…DA release in the nucleus accumbens (NAcc) is a critical substrate mediating locomotor behavior. Cholecystokinin (CCK) is co-localized with dopamine (DA) in up…”
Get full text

Combining Iclepertin (BI 425809) With Computerized Cognitive Training in Patients With Schizophrenia: Baseline Data From an Ongoing Phase II Trial by McDonald, Sean, Fu, Eric, Wunderlich, Glen, Harvey, Philip D.

“…Abstract Introduction There are currently no approved pharmacotherapies to treat cognitive impairment associated with schizophrenia (CIAS). Iclepertin (BI…”
Get full text

Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women: Efficacy of Flibanserin in the VIOLET Study by DeRogatis, Leonard R., Komer, Lawrence, Katz, Molly, Moreau, Michèle, Kimura, Toshio, Garcia Jr, Miguel, Wunderlich, Glen, Pyke, Robert

“…Hypoactive Sexual Desire Disorder (HSDD) is the most common form of Female Sexual Dysfunction and is characterized by low sexual desire that causes distress…”
Get full text

P1‐062: A PHASE II STUDY EVALUATING EFFICACY, SAFETY, AND TOLERABILITY OF ORAL BI 425809 IN PATIENTS WITH COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE DEMENTIA by Wunderlich, Glen, Jessen, Frank, Garcia, Miguel, Blahova, Zuzana

Get full text

A PHASE II STUDY EVALUATING EFFICACY, SAFETY, AND TOLERABILITY OF ORAL BI 425809 IN PATIENTS WITH COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE DEMENTIA by Wunderlich, Glen, Jessen, Frank, Garcia, Miguel, Blahova, Zuzana

Get full text

Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study by Tsuda, Yasuhiro, Ugai, Hiroyuki, Wunderlich, Glen, Shin, Jae-Gook

“…This study's primary goal was to evaluate the safety profile, tolerability, pharmacokinetics, and dose proportionality of BI 425809, a potent and selective…”
Get full text

Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study by Desch, Michael, Schlecker, Christina, Hohl, Kathrin, Liesenfeld, Karl-Heinz, Chan, Tom, Müller, Fabian, Wunderlich, Glen, Keller, Sascha, Ishiguro, Naoki, Wind, Sven

“…Glycine transporter-1 inhibitors may ameliorate cognitive deficits in schizophrenia. This study evaluated potential drug-drug interactions with the glycine…”
Get full text

Efficacy and Safety of Iclepertin (BI 425809) in Patients With Schizophrenia: CONNEX, A Phase III Randomized Controlled Trial Program by Wunderlich, Glen, Blahova, Zuzana, Hake, Sanjay, Ikezawa, Satoru, Marder, Stephen, Falkai, Peter, Krystal, John H.

“…Abstract Introduction Cognitive impairment is a major determinant of poor functional outcome in schizophrenia and there are currently no available…”
Get full text